Aura Biosciences Reports Q3 GAAP EPS of -$0.29 and Strong Cash Position
Aura Biosciences (AURA) has reported its third-quarter financial results, posting a GAAP earnings per share (EPS) loss of $0.29. Despite the quarterly loss, the company maintains a robust liquidity position with $297.2 million in cash, cash equivalents, and marketable securities as of September 30, 2024. The biotechnology firm anticipates that its current capital reserves are sufficient to fund operations through the first half of 2029. This extended runway provides a significant buffer for the company's ongoing clinical development programs in ocular oncology.
Tickers: $AURA
Topics: cash runway earnings report financial results
Read the full article at Seeking Alpha
Part of the story OnKure Therapeutics Reports Q3 GAAP EPS of -$0.36 and Strong Cash Runway (7 articles)